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Abstract
Objective: Serum levels of soluble TNF-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor CD163 (sCD163)
have been linked to insulin resistance. We analysed the usefulness of these cytokines as biomarkers of type 2 diabetes in a
Spanish cohort, together with their relationship to food consumption in the setting of the Di@bet.es study.
Research Design and Methods: This is a cross-sectional, matched case-control study of 514 type 2 diabetes subjects and
517 controls with a Normal Oral Glucose Tolerance Test (NOGTT), using data from the Di@bet.es study. Study variables
included clinical and demographic structured survey, food frequency questionnaire and physical examination. Serum
concentrations of sTWEAK and sCD163 were measured by ELISA. Linear regression analysis determined which variables were
related to sTWEAK and sCD163 levels. Logistic regression analysis was used to estimate odd ratios of presenting type 2
diabetes.
Results: sCD163 concentrations and sCD163/sTWEAK ratio were 11.0% and 15.0% higher, respectively, (P,0.001) in type 2
diabetes than in controls. Following adjustment for various confounders, the OR for presenting type 2 diabetes in subjects
in the highest vs the lowest tertile of sCD163 was [(OR), 2,01 (95%CI, 1,46–2,97); P for trend ,0.001]. Coffee and red wine
consumption was negatively associated with serum levels of sCD163 (P= 0.0001 and; P= 0.002 for coffee and red wine
intake, respectively).
Conclusions: High circulating levels of sCD163 are associated with type 2 diabetes in the Spanish population. The
association between coffee and red wine intake and these biomarkers deserves further study to confirm its potential role in
type 2 diabetes.
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Introduction
Common diabetes risk factors offer limited ability to identify
subjects at risk of developing type 2 diabetes mellitus. Conse-
quently, cross sectional epidemiological studies are being under-
taken to identify new biomarkers to estimate better this risk.
Classically, inflammatory markers have been one of the most
widely explored in different cohorts, but results to date are far
from conclusive [1].
Recently, the inflammatory imbalance between pro-inflamma-
tory and anti-inflammatory molecules is gaining attention as an
approach to interpret a specific metabolic scenario in which a
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chronic low inflammatory environment is a typical event [2] [3].
Tumor necrosis factor weak inducer of apoptosis (TWEAK), a
cytokine member of the TNF- family, has emerged as a Janus-
faced molecule, functioning as a pro-inflammatory cytokine in
autoimmune diseases [4] [5], but with anti-inflammatory behavior
in many high cardiovascular (CV) risk morbidities, such as type 2
diabetes [3] [6].
TWEAK has two protein forms, a full-length form which
contains the transmembrane domain (mTWEAK), and a smaller
secreted soluble form that is released into the circulation after
proteolytic cleavage by a furin (sTWEAK) [7] [8]. Reduced
circulating sTWEAK levels have been demonstrated in patients
with type 2 diabetes suffering from chronic renal failure, and in
subjects with increased atherosclerosis or type 1 diabetes [9]
[10][11] [12]. Recently, in a prospective follow-up study of a high
CV risk cohort, we found that sTWEAK appears to have
predictive value as a marker in the development of type 2
diabetes, highlighting a possible pathogenic role of sTWEAK in
this disease [13] [14].
Circulating levels of sTWEAK could be modulated, in part, by
a scavenger receptor termed CD163 (Cluster of Differentiation
163). This protein, encoded by the CD163 gene, is a member of
the scavenger receptor cysteine-rich (SRCR) superfamily, and is
exclusively expressed in monocytes and macrophages. CD163 is
also released as a soluble form in the circulation (sCD163). It has
been postulated that macrophages can recognize and internalize
sTWEAK, thereby decreasing its plasma concentration [15];
although this is controversial [16]. High circulating levels of
sCD163 have been linked with a more pro-inflammatory profile
since it has recently been associated with long-term occurrence of
type 2 diabetes in a Danish cohort, underscoring its role as a
potential biomarker of diabetes [17].
Dietary-induced weight loss has been shown to modify
circulating levels of sCD163 in obese patients [18]. Also, it is well
known that the adherence to a healthy diet, such as Mediterranean
diet and certain food consumption, are associated with an
improvement in the inflammatory environment and a reduced
risk of diabetes, both in prospective [19] and intervention studies
[20] [21].
In view of these observations, we hypothesized that the chronic
inflammatory imbalance in patients with type 2 diabetes may be
linked to sCD163 and/or sTWEAK levels and in turn, this might
be influenced by the type of food consumption.
We have used a wide-population based cross-sectional Spanish
survey to test the concurrence of differences in circulating levels of
these proteins in subjects with type 2 diabetes, exploring the
influence of food consumption on plasma level variability.
Research Design and Methods
Study population
Cross-sectional, case-control study of 514 type 2 diabetes
subjects and 517 controls (normal an oral glucose tolerance test
(NOGTT), namely fasting glucose ,110 mg/dL and post OGTT
glucose ,140 mg/dL) matched by sex, age and BMI, using data
from the Di@bet.es study [22]. The Di@bet.es study was a nation-
wide, cross-sectional, population-based survey conducted between
2009 and 2010. A cluster sampling design (100 health centers
randomly selected with a probability proportional to population
size) was used to select participants, forming a representative
random sample of the Spanish population. For the analysis
presented here, all diabetic subjects from the original Di@bet.es
study were selected and matched with controls selected from the
same population [23].
The study was approved by the Ethics and Clinical Investiga-
tion Committee of Hospital Regional Universitario (Malaga,
Spain) in addition to other regional ethics and clinical investigation
committees throughout Spain, and written informed consent was
obtained from all participants.
Variables and procedures
Participants were invited by mail and/or telephone to attend
one examination visit at their health center. Information was
collected using an interviewer-administered structured question-
naire, followed by a physical examination by a nurse. Fasting
blood sampling and OGTT were performed.
Socio-demographic data collected included age, sex, smoking
status (current smoker, ex-smoker or never smoker), and personal
history of diabetes and hypertension.
Weight, height and waist and hip circumferences were
measured by standardized methods [19]. The body mass index
(BMI) and waist-to-hip ratio (WHR) were calculated as weight/
height2 (kg/m2) and waist/hip (both in cm), respectively.
Blood pressure was measured using a blood pressure monitor
(Hem-703C, Omron, Barcelona, Spain) following the manufac-
turer’s instructions. Blood pressure was measured with the subject
seated and after 5 minutes of rest. Two readings were obtained
and the mean value was used in the analyses.
A qualitative food frequency questionnaire (FFQ) was admin-
istered face-to-face by a trained dietitian [24]. Annual frequency
consumption of 50 food items were specified in 11 different
categories as follows: never/seldom, 1 and 2–3 times/month, 1, 2–
3 and 4–6 times/week and 1, 2, 3, 4 and .4 times/day. For this
study, food items in the FFQ were grouped in 34 categories
(Table 1) and the type of oil used for either dressing, cooking,
frying or making mayonnaise was queried.
Subjects with baseline capillary blood glucose levels lower than
7.8 mmol/L (140 mg/dL) and those not currently receiving
treatment for diabetes underwent a standard OGTT. A venous
blood sample was taken from each subject (overnight fast and post
load). Samples were immediately centrifuged and stored at 218uC
(15 days maximum) until shipment to the centralized CIBERDEM
Biobank, where the samples were stored at 280uC for later
analysis.
Serum glucose, triglycerides, and cholesterol were measured
enzymatically, and HDL-Cholesterol by a direct method on an
Artchitect C8000 Analyzer (Abott Laboratories SA, Madrid,
Spain). Serum insulin was measured by immunochemilumines-
cence on an Architect I8000 Analyzer (Abbott Laboratories SA).
The homeostatic model assessment insulin resistance index
(HOMA-IR) was calculated by the formula: (serum glucose
(mmol/L) x serum insulin (mU/L))/22.5.
The diagnosis and classification of diabetes was based on plasma
glucose results, using the 1999 WHO criteria [25].
Obesity was considered to be a BMI $30 kg/m2, and
abdominal obesity a waist circumference .102 cm in men or .
88 cm in women.
Hypertension was defined as ongoing antihypertensive treat-
ment or systolic blood pressure $140 mmHg and/or diastolic
blood pressure $90 mmHg.
Serum concentrations of sTWEAK and sCD163 were deter-
mined in duplicate by ELISA using the commercially available,
human TWEAK/TNFSF12 kit #DY1090, and human CD163
kit #DY1607 (R&D Systems Europe, Abingdon, Oxon, UK),
respectively. The intra- and inter-assay CVs were 2.5% and 7.0%
for sTWEAK, and 2.4% and 6.4% for sCD163, respectively. The
sensitivity of the test was of 62 pg/mL for sTWEAK and 1.56 ng/
mL for sCD163.
sCD163 Association with Type 2 Diabetes
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Table 1. Clinical, anthropometrical and food habits of the study groups.
T2DM NOGTT P
n 514 517 –
Age 64.9611.7 64.9611.8 0.9
% Men 54.5 54.5 1
BMI (kg/m2) 30.264.4 30.164.4 0.6
WHR 0.9760.08 0.9460.08 0.0001
SBP (mmHg) 146.4620.0 141.2618.4 0.0001
DBP (mmHg) 81.1610.6 79.669.4 0.07
Smoking (%) 16.8 15.9 0.7
Treatment with antidiabetic drugs and/or insulin 61.6 – –
Treatment with lipid-lowering drugs (%) 35.2 23.8 0.001
Serum concentrations* :
sTWEAK (pg/mL) 645.7 (391.0–1254.2) 665.1 (425.0–1242.7) 0.8**
sCD163 (ng/mL ) 181.5 (148.1–221.7) 163.5 (131.2–200.9) 0.0001**
sCD163/sTWEAK index 0.23 (0.12–0.45) 0.20 (0.12–0.37) 0.001**
HOMA-IR index 3.2 (1.9–5.1) 1.8 (1.3–2.6) 0.0001**
CRP (mg/L) 2.8 (1.3–5.2) 2.1 (1.1–4.1) 0.01**
Cholesterol mg/dL 192 (168–222) 204 (179–228 ) 0.0001***
HDL-Cholesterol mg/dL 45 (38–54) 48 (42–57) 0.0001***
Triglycerides mg/dL 136 (98–202) 111 (84–146) 0.0001***
LDL-Cholesterol mg/dL 102 (82–122) 109 (93–131) 0.0001***
Percentage (%) of people who take a serving at least once a day of:
Breakfast cereals 2.8 5.2 0.06
White bread 80.4 84.3 0.1
Whole bread 19.4 18.6 0.8
Sugar, honey, candy, jam and similar 25.2 67.7 ,0.0001
Chocolate 6.4 12.7 0.001
Cakes, muffins and similar 27.5 36.4 0.002
Eggs 13.1 10.7 0.2
Dairy 63.7 68.2 0.1
Milkshake, pudding, custard, ice cream 6 6.2 0.8
Butter, cream, lard 3 3.2 0.9
Margarine 9.2 6.4 0.1
Salads (raw vegetables) 38.1 38.3 0.9
Vegetables as a main course or side dish 10.3 9.3 0.6
Stews with some vegetables 8.6 6.7 0.3
Potatoes 8.2 10.8 0.1
Fresh fruit and juices 81.1 84.7 0.1
Nuts 8.8 13.1 0.03
Snacks and appetizers 0.9 1.5 0.5
Meat 15.9 16.1 0.9
Sausage 14.6 11.2 0.1
Red wine 22.5 23.3 0.7
Other types of wine 5.2 6.6 0.3
Beer 9.9 11.8 0.3
Liqueurs and spirits 2.8 2.3 0.5
Any type of alcoholic beverage 33.9 39.5 0.05
Sugared soft drinks 8.2 8.4 0.9
Sugar free soda 8.4 3.8 0.002
Caffeinated coffee 41.8 48.4 0.03
Decaffeinated coffee 38.6 32.3 0.03
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Plasma concentrations of high-sensitivity C-reactive protein
(CRP) was determined by a highly sensitive immunonephelometry
kit (Dade Behring, Marburg, Germany). CRP cut-off value to
exclude acute inflammation was 10 mg/L.
Statistical analysis
Statistical analysis was performed using the SPSS/PC statistical
package (version 19 for Windows; SPSS, Chicago, IL). For clinical
and anthropometric variables, normal distributed data was
expressed as mean value and SD, and for variables with no
Gaussian distribution, values were expressed as median (25–75th
percentile). For statistical analysis, values of variables that did not
have a Gaussian distribution were logarithmically transformed.
The hypothesis testing for continuous variables was performed
using t-test (or the Mann-Whitney test in the event of non-
normality of distributions). Associations between the qualitative
characteristics were tested by x2 test. Linear regression analysis
was used to determine what variables were related to sTWEAK
and sCD163 serum concentrations.
Logistic regression analysis was used to estimate odd ratios of
presenting type 2 diabetes. Results were expressed as standardized
coefficient (b) and 95% confidence interval for b [95% CI(B)]. To
evaluate dose-response relationships, P values for trend were
calculated. In all cases the level of rejection of a null hypothesis
was a,0.05.
Results
The characteristics of the studied population are shown in
Table 1. Groups were similar in age, sex ratio and BMI, however
type 2 diabetes patients had higher WHR and blood pressure.
Smoking habit was similar in both groups. Type 2 diabetes
mellitus patients were treated with anti-diabetic drugs and/or
insulin in 61.6% of cases and lipid-lowering drugs were taken by
35.2% of diabetes patients and 23.8% of NOGTT subjects. No
differences were found in serum sTWEAK levels between study
groups, but serum sCD163 levels, sCD163/sTWEAK index, C-
reactive protein (CRP) and HOMA-IR were increased in patients
with type 2 diabetes in 11.0%, 15.0%, 33.3% and 77.7%
respectively, after adjusting for WHR and systolic blood pressure.
Serum lipids were different between studied groups even when
adjusted by WHR, SBP and lipid-lowering drug treatment.
The association between the presence of diabetes and the
frequency of intake of selected food groups was also analysed
(Table 1). People with type 2 diabetes often take less cereals, sugars
(honey, candy, jam and similar), chocolate, cakes, nuts, alcoholic
beverages, sugared soft drinks and caffeinated coffee in general
and, take more often decaffeinated coffee and sugar free soft
drinks.
Spearman bivariate correlation analysis with the entire studied
population showed that sTWEAK, sCD163 and sCD163/
sTWEAK index were weakly and significantly related with fasting
glucose (r =20.08, P,0.01; r = 0.13, P,0.001; and r = 0.11, P,
0.01 respectively); WHR (r =20.07, P,0.01; r = 0.06, P,0.01;
r = 0.1, P,0.001, respectively), and HOMA-IR (r =20.06, P,
0.01; r = 0.21, P,0.001; r = 0.14, P,0.001; respectively), although
relations were direct with sCD163 and sCD163/sTWEAK index,
and reverse with sTWEAK. Additionally, a weak but significantly
positive relation was found between sCD163 and BMI (r = 0.09,
P,0.001).
Levels of sTWEAK, sCD163 and sCD163/sTWEAK index
were also analyzed in relation to food intake. The intake of each
food item was coded into two categories, as shown in Table 1.
Univariate analysis showed that sTWEAK levels were different
according to the intake of cereals, margarine and caffeinated
coffee (P,0.05, data not shown). Levels of sCD163 were different
depending on the intake of olive oil, sweets, cakes, meat, canned
fish, wine, coffee, eggs, butter, vegetables and legumes (P,0.05,
data not shown). The sCD163/sTWEAK index was found
associated to foods in a similar manner to sCD163.
Regression analysis showed that, after adjusting for several
confounding variables, caffeinated coffee and red wine intake were
the only foods that remained associated solely with sCD163 (b=2
0.062, P= 0.05 and b=20.108, P= 0.001 respectively, Table 2).
The association between the sCD163/sTWEAK index and
HOMA-IR remained in the adjusted models (b= 0.096,
P= 0.009, Table 2), in contrast to that of sTWEAK or sCD163
(Table 2).
Interaction between type 2 diabetes and variables shown in
Table 2 was not significant, thus the major associations with the
Table 1. Cont.
T2DM NOGTT P
Tea 5.4 5.1 0.8
Percentage (%) of people who take a serving at least twice a week of:
Rice, Italian pasta and similar 19.4 18.7 0.8
Pulses (lentils, beans, chickpeas) 6.4 6.9 0.7
Fresh fish and seafood 15.5 20 0.06
Canned fish and seafood 7.9 6.7 0.4
Percentage (%) of people who take always olive oil for:
Seasoning 96.6 97.2 0.7
Cooking 91.4 91.9 0.8
Frying 73 76 0.2
Mayonnaise 50 49.9 0.9
*Data are median (IQR).
**Adjusted by WHR and SBP.
***Adjusted by WHR, SBP and lipid-lowering drugs treatment.
T2DM; Type 2 diabetes mellitus; NOGTT, Normal oral glucose tolerance test; BMI; Body mass Index; WHR; Waist to hip ratio; SBP; Systolic Blood Pressure, DBP;
Diastolic Blood pressure; HOMA-IR homeostatic model assessment insulin resistance index; CRP, C-reactive protein.
doi:10.1371/journal.pone.0101250.t001
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included variables were reported in Table 3. We found that
sTWEAK levels were not different according to sex, BMI,
abdominal obesity or high blood pressure presence; neither were
they different with respect to coffee, decaffeinated coffee or red
wine intake, but sTWEAK levels were moderately increased in
non-smoking subjects.
However, sCD163 was significantly increased in women, in
subjects with BMI $30, abdominal obesity, high blood pressure
and with active smoking status, and decreased in subjects taking
caffeinated coffee or red wine at least once per day. The sCD163/
sTWEAK index was increased in people with abdominal obesity,
but did not change with any other variable.
In the multivariate analysis, to calculate the likelihood of having
diabetes adjusted by abdominal obesity, high blood pressure, and
coffee and red wine intake (logistic regression, Table 4), subjects
with serum values of sCD163 in tertile 3 had twice the risk of
diabetes compared with subjects with serum values in the lower
tertile 1 (P for trend#0.0001). However, lower circulating levels of
sTWEAK were not associated with the presence of diabetes (P for
trend = 0.1), but sTWEAK tertile 2 with respect to tertile 1 were
found associated; this data is not considered of importance since
tertile 3 versus tertile 1 is not associated. Smoking did not alter the
results (data not shown).
Discussion
In this study we report that circulating levels of sCD163 are
associated with type 2 diabetes in a Spanish population and these
levels may be influenced by coffee and red wine consumption.
Several epidemiological studies have associated inflammation to
type 2 diabetes [26] [27]. Elevated levels of clinical markers and
inflammation mediators may be reduced after intensive life-style
modifications. Furthermore, experimental data showing a link
between insulin resistance and different inflammatory candidates
have suggested that inflammation is intimately involved in the
pathogenesis of type 2 diabetes. Accordingly, the search for useful
serum biomarkers remains a major focus in many epidemiological
studies. Recently, circulating soluble levels of sCD163 have been
linked to long-term onset of type 2 diabetes in a Danish cohort,
proposing its clinical utility as a biomarker of diabetes [17].
Previous data on obesity, a condition usually linked with insulin-
resistance and low chronic inflammation, revealed that circulating
levels of sCD163 mirrored particular inflammatory markers such
as CRP and TNFa [28]. Consistent with these findings, a close
relationship between sCD163 and BMI, WHR and HOMA-IR
was demonstrated in our study cohort. Furthermore, a positive
association with CRP was detected also in our study. Thus, high
circulating levels of sCD163 were associated with a higher
prevalence of type 2 diabetes in this Spanish population.
Nevertheless, sTWEAK levels were not linked with a protective
cardiovascular profile in this study. Generally, studies conducted in
high CV risk populations indicate that low levels of sTWEAK may
point to a worse scenario [11]. A recent study highlighted the
relevance of decreased serum sTWEAK as a predictive marker of
type 2 diabetes. Interestingly this study was conducted in a high
CV risk population, in which the incidence of type 2 diabetes was
assessed during a follow up [13]. In this large prospective nested
case-control study, lower sTWEAK serum levels were found in
incident cases compared to matched controls. Indeed, previous
cross-sectional studies have also proposed a link between
sTWEAK concentration and type 2 diabetes [10]. However, in
our case-control study, we did not find a clear association of
sTWEAK and the presence of type 2 diabetes. Differences
between studies could be explained by differences in cohort
definitions. Our subjects came from a random general population
without bias for any special cardiovascular risk factor. This may
have reduced the power of sTWEAK as a useful biomarker, as was
proposed in previous reports. Of note, we cannot discard a
potential effect of this cytokine in type 2 diabetes because of the
inherent limitation of a cross-sectional design. We are aware that a
prospective follow-up study would be more appropriate to
unequivocally confer or deny a role in type 2 diabetes occurrence,
but the data presented in this work tempers the usefulness of
sTWEAK as a biomarker of type 2 diabetes in a general
population.
With respect to dietary habits, we have observed a strong
inverse relationship between sCD163 levels and some foods
typically associated with a reduced risk of diabetes, such as coffee
and red wine. Although we did not find a direct association
between sCD163 and type 2 diabetes, it is well known that diet
might have important effects on mediators of inflammation [29]
[30]. Consequently, our results provide the first indication for an
inverse relationship between coffee and red wine and circulating
levels of sCD163. These data are compatible with the available
reports describing the beneficial effect of moderate consumption of
Table 2. Relationship of sCD163, sTWEAK and sCD163/sTWEAK index with caffeinated coffee and red wine.
Log sTWEAK Log sCD163 Log sCD163/sTWEAK index
Standarized
b coefficient p
Standarized
b coefficient p
Standarized
b coefficient p
Sex 0.054 0.1 0.077 0.04 –0.015 0.6
Age –0.018 0.6 0.020 0.5 0.019 0.5
Coffee intake –0.024 0.4 –0.062 0.05 –0.031 0.3
Red wine intake –0.013 0.6 –0.108 0.001 –0.036 0.2
WHR –0.036 0.3 0.072 0.05 0.061 0.1
SBP 0.001 0.9 –0.008 0.8 –0.007 0.8
Diabetes presence –0.001 0.9 0.094 0.006 0.067 0.05
Log_HOMA-IR –0.050 0.1 0.054 0.1 0.096 0.009
Log_CRP 0.002 0.9 0.06 0.06 0.02 0.5
R2 of the adjusted model 0.01 0.3 0.06 0.001 0.03 0.001
doi:10.1371/journal.pone.0101250.t002
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coffee and wine in delaying the onset of type 2 diabetes; however,
no causal effect can be inferred from the study design. [31].
Epidemiologic studies have consistently linked coffee consumption
with a lower risk of type 2 diabetes [32]. In human trials,
consumption of eight cups of coffee per day significantly decreases
plasma levels of proinflammatory cytokines such as IL-18, together
with significant increases in adiponectin levels [33]. Similarly,
coffee consumption has been inversely associated with markers of
inflammation and endothelial dysfunction both in healthy women
and those with type 2 diabetes [34]. Experimental data in a mouse
Table 3. Serum concentrations of sTWEAK. sCD163 and sCD163/sTWEAK index according to characteristics of the studied subjects.
TWEAK pg/ml CD163 ng/ml sCD163/sTWEAK index
Men 603.8 (392.8–1236.7) 166.7 (133.2–205.7) 0.21(0.13–0.41)
Women 726.5(429.5–1266.6) 179.2(144.6–216.1) 0.22(0.13–0.41)
p 0.1 0.001 0.8
BMI,30 663.0(404.3–1247.4) 167.8(134.3–203.9) 0.21(0.13–0.40)
BMI$30 648.2(407.5–1251.4) 179.6(142.3–220.0) 0.22(0.13–0.43)
P 0.9 0.0001 0.07
Abdominal obesity (sex adjusted)
No 585.9(400.6–1238.3) 163.5(129.8–199.6) 0.21(0.13–0.39)
Yes 693.5(411.4–1251.4) 180.4(145.5–220.6) 0.22(0.13–0.43)
p 0.3 0.0001 0.04
High blood pressure 612.4(406.0–1232.9) 166.3(133.2–203.0) 0.22(0.13–0.40)
No high blood pressure 672.1(405.1–1254.7) 175.5(139.5–213.5) 0.22(0.13–0.42)
p 0.6 0.01 0.5
Smoking 610.2(392.2–1160.8) 162.0(126.7–196.6) 0.21(0.13–0.40)
No smoking 673.3(409.7–1258.6) 175.2(140.4–213.1) 0.22(0.13–0.41)
p 0.05 0.001 0.7
Coffee less than one cup per day 788.2(406.6–1290.1) 179.4(142.3–221.1) 0.21(0.13–0.41)
Coffee at least one cup per day 578.0(404.9–1196.5) 166.0(133.0–203.1) 0.22(0.13–0.41)
p 0.07 0.0001 0.9
Decaffeinated coffee less than one cup per day 665.2(406.3–1266.3) 170.4(138.0–208.4) 0.21(0.13–0.41)
Decaffeinated coffee one or more cups per day 661.2(404.3–1237.7) 177.2(139.1–216.3) 0.24(0.13–0.41)
p 0.1 0.1 0.7
Red wine less than one drink per day 658.7(410.9–1255.2) 175.4(140.6–215.9) 0.23(0.13–0.41)
Red wine one or more drinks per day 703.2(383.7–1242.5) 164.0(129.7–201.2) 0.19(0.13–0.40)
p 0.5 0.002 0.07
doi:10.1371/journal.pone.0101250.t003
Table 4. Likelihood of having diabetes (T2DM=1; control = 0) according to selected variables of interest.
95% CI of OR
P- value OR Low High P-for trend
One or more cups of caffeinated coffee per day 0.1 1.19 0.91 1.56
One or more drinks of red wine per day 0.3 1.17 0.86 1.59
sTWEAK tertile 1 (,448 pg/mL. reference) 1
sTWEAK tertile 2 (449–1040 pg/mL) 0.04 0.72 0.52 0.99 0.1
sTWEAK tertile 3 (.1041 pg/mL) 0.1 0.77 0.56 1.06
sCD163 tertile 1 (,149 ng/mL. reference) 1
sCD163 tertile 2 (150–197 ng/mL) 0.008 1.52 1.11 2.09 #0.001
sCD163 tertile 3 (.197 ng/mL) 0.0001 2.01 1.46 2.77
Abdominal obesity 0.0001 2.06 1.58 2.69
High blood pressure 0.0001 1.71 1.26 2.31
CI: confidence interval; OR: odds ratio.
doi:10.1371/journal.pone.0101250.t004
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model of diabetes also confirm a suppressive effect of coffee
consumption on hyperglycemia, by improving insulin sensitivity in
part due to reducing inflammatory cytokine expression and
decreasing fat liver accumulation [35]. Caffeine has multiple
actions on physiology, including inhibition of the DNA damage
response, and its metabolites 1-methylxanthine and 1-methyluric
acid are potent antioxidants [36]. However, the effects of caffeine
on sCD163 release have not yet been investigated.
Equally, a negative association was also observed between
sCD163 levels and red wine consumption. A recent study has
shown that the Mediterranean diet, rich in polyphenols, reduces
the incidence of type 2 diabetes [37]. In vitro, wine polyphenols,
particularly the flavonoids procianidins from grape reduces
expression of pro-inflammatory cytokines such as MCP-1, IL-6
and TNF-a by inhibiting NF-kB nuclear translocation [38].
Notwithstanding the results observed, we should highlight that the
frequency nutritional survey was not quantitative; therefore, we
cannot measure whether these effects are due to the amount of
caffeine or other active compounds in foods.
We found reduced levels of circulating sTWEAK and sCD163
in smokers. These data corroborate our previous findings on
sTWEAK in smokers [13]. The potential influence of smoking on
sTWEAK levels appears to be a complex issue that remains to be
fully elucidated. Unexpectedly, levels of sCD163 were also found
to be reduced in smokers compared with non-smokers. Data
concerning the effect of smoking on inflammation appears to be
contradictory; whilst cigarette smoke has been associated with
oxidative stress and an inflammatory response [39], others have
reported that nicotine, a major constituent of tobacco smoke,
exerts anti-inflammatory effects on different cell types and appears
to be beneficial in disorders where inflammation-related mecha-
nisms are involved, including ulcerative colitis and obesity [40]
[41].
In summary, the data presented here provide new evidence for
the participation of sCD163/sTWEAK binomial on the preva-
lence of type 2 diabetes in the general population. Furthermore,
food consumption may influence the circulatory cytokine profile
related to sCD163, as coffee and red wine associated with a more
anti-inflammatory profile. New prospective studies are required to
confirm the pathogenic link between these associations.
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